CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,001–1,100 of 1,725
Novel off-Targeting Events Identified after Genome Wide Analysis of CRISPR-Cas Edited Pigs
Redel, B. K., Yoon, J. D., Reese, E. D., An, H., Uh, K., Chen, P. R., Prather, R. S., & Lee, K. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0012 · Cited by 6
“40,41 Our fi nding will offer a guideline to detect off-targeting events in pigs for biomedical applications and imply the level of off-targeting events that could be encountered while applying genome editing technology in the clinics.”
A Milestone for Gene-Editing Therapies
Musunuru, K. (2024) · New England Journal of Medicine · doi:10.1056/nejme2412176 · Cited by 5
Peña-Gutiérrez, I., Olalla-Sastre, B., Río, P., & Rodríguez-Madoz, J. R. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.10.010 · Cited by 6
Catalytic Photooxygenation Demonstrates Therapeutic Efficacy in Transthyretin Amyloidosis
Yamane, M., Umeda, H., Toyobe, M., Iwai, A., Ishihara, K., Kudo, G., Mitsunuma, H., Hori, Y., Tomita, T., Mizuguchi, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06205 · Cited by 5
Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids
Landmesser, U., Thum, T., Tokgözoğlu, L., Guzik, T. J., Cosentino, F., Hajjar, R. J., Gonçalves, A., Laguna-Fernández, A., Nioi, P., Prochaska, J. H., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf520 · Cited by 7
Prenatal Gene Therapy for Metabolic Disorders
Coons, B. E., & Peranteau, W. H. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000662 · Cited by 7
Approved gene therapies in Australia: coming to a store near you
Mallik, S., Bailey, C. G., & Rasko, J. E. J. (2022) · Internal Medicine Journal · doi:10.1111/imj.15880 · Cited by 5
Therapeutic tools for inherited neuropathies
Péréon, Y. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.12.001 · Cited by 4
Optimizing the Cas13 antiviral train: cargo and delivery
Sharma, S., & Myhrvold, C. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217146 · Cited by 5
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis
Zhang, W., Ding, J., Wang, W., Wang, D., Pan, Y., & Xu, D. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s414821 · Cited by 5
“Another promising therapeutic is the RISPR-Cas9 system for gene editing, which was validated in some cohort studies and needs further validation by randomized trials.(52,53)”
MethodCRISPR-based m6A modification and its potential applications in telomerase regulation
Yi, M., Wang, M., Xu, Y., Cao, Z., Ling, Y., Zhang, Z., & Cao, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1200734 · Cited by 6
Self-citationFuture prospects in mRNA vaccine development
Mbatha, L. S., Akinyelu, J., Maiyo, F., & Kudanga, T. (2023) · Biomedical Materials · doi:10.1088/1748-605x/aceceb · Cited by 8
Clinical trials in Charcot-Marie-Tooth disorders: a retrospective and preclinical assessment
Nair, M. A., Niu, Z., Madigan, N., Shin, A. Y., Brault, J. S., Staff, N. P., & Klein, C. J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1251885 · Cited by 5
“Recently, drug-based genetic therapies have begun to emerge in other neuromuscular disorders including spinal muscular atrophy (6), transthyretin amyloidosis (7, 8), and adrenal leukodystrophy (9).”
BackgroundNon‐Viral RNA Delivery During Pregnancy: Opportunities and Challenges
Chaudhary, N., Newby, A. N., & Whitehead, K. A. (2023) · Small · doi:10.1002/smll.202306134 · Cited by 13
Ogieuhi, I. J., Ugiomoh, O. M.-A., Muzofa, K., et al. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00517-y · Cited by 5
“(Y Ando) Ntla-2001, a DNA editor in Phase 1 development, causes up to 87% TTR knockdown with once annual dosing [63].”
BackgroundPolysorbate 80-containing ionizable lipid nanoparticles for mRNA delivery
Tang, X., Ding, S., Yang, S., Cheng, Y., Liu, H., Chen, K., & Han, X. (2024) · Biomaterials Science · doi:10.1039/d4bm00523f · Cited by 5
Uncovering the knowledge about systemic amyloidosis relevant to the rheumatologists
Pereira, I. A., Neto, N. S. R., do Nascimento, R. R. N. R., et al. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00399-3 · Cited by 5
Emerging CRISPR Therapies for Precision Gene Editing and Modulation in the Cardiovascular Clinic
Legere, N., & Hinson, J. T. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02125-3 · Cited by 8
“This disease is known to be caused by inheritance of over 100 TTR mutations that are thought to increase protein misfolding and aggregation in cardiac interstitial tissue, which can progressively cause cardiac dysfunction and death [15, 16].”
Benati, D., Cattin, E., Corradi, F., Ferrari, T., Pedrazzoli, E., Patrizi, C., Marchionni, M., Bertorelli, R., Sanctis, V. D., Merlini, L., et al. (2024) · Biomolecules · doi:10.3390/biom14111412 · Cited by 6
From Molecular to Radionuclide and Pharmacological Aspects in Transthyretin Cardiac Amyloidosis
Stanciu, S. M., Jurcut, R. O., Galrinho, R. D., Ștefani, C., Miricescu, D., Rusu, I. R., Prisacariu, G. S., & Mititelu, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010146 · Cited by 7
Kassim, S. H., Urnov, F. D., Musunuru, K., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02744-3 · Cited by 5
Du, S. W., Palczewska, G., Dong, Z., Lauterborn, J. C., Kaipa, B. R., Yan, A. L., Hołubowicz, R., Ha, S., Chen, P., Gall, C. M., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2506257122 · Cited by 7
Glyco-nanomaterials as a therapeutic target in drug delivery and biomedicine: A review
Dessai, A. D., Nair, A., Selvasudha, N., Garg, S., & Nayak, U. Y. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147830 · Cited by 8
Pathak, G. A., Lillo, A. D., Wendt, F. R., Angelis, F. D., Koller, D., Cabrera‐Mendoza, B., Jacoby, D. L., Miller, E. J., Buxbaum, J. N., & Polimanti, R. A. (2021) · Amyloid · doi:10.1080/13506129.2021.2018678 · Cited by 14
“protein in the circulation [24-27], our study lacks information related to the amount of TTR protein synthesized and secreted in response to the increase in hepatic transcription.”
BackgroundClinical gene technology in Australia: building on solid foundations
O’Sullivan, G. M., Philips, J. G., & Rasko, J. E. J. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51629 · Cited by 5
Sconocchia, T., Foßelteder, J., Köhnke, T., Majeti, R., & Reinisch, A. (2023) · Journal of Visualized Experiments · doi:10.3791/64558-v · Cited by 6
The Need for Transfer Learning in CRISPR-Cas Off-Target ScoringPreprint
Kota, P. K., Pan, Y., Vu, H.-A., Cao, M., Baraniuk, R. G., & Bao, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.28.457846 · Cited by 3
“other and with validated in vivo editing [22, 30].”
BackgroundA extrafiscalidade e os controles de proporcionalidade e de igualdade
Papadopol, M. D. (2009) · Americanae (AECID Library) · Cited by 7
Comprehensive Analysis of CRISPR Base Editing Outcomes for Multimeric ProteinPreprint
Kabra, M., Moosajee, M., Newby, G. A., Molugu, K., Saha, K., Liu, D. R., & Pattnaik, B. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.20.496792 · Cited by 3
Programmable enveloped delivery vehicles for human genome engineering in vivoPreprint
Hamilton, J. R., Chen, E., Perez, B. S., Espinoza, C. R. S., Kang, M. H., Trinidad, M. I., & Doudna, J. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.24.505004 · Cited by 5
Secreted Particle Information Transfer (SPIT) – A Cellular Platform for In Vivo Genetic EngineeringPreprint
Charlesworth, C. T., Homma, S., Suchy, F. P., Wang, S., Bhadury, J., Amaya, A. K., Camarena, J., Zhang, J., Tan, T.-K., Igarashi, K. J., et al. (2024) · Research Square · doi:10.1101/2024.01.11.575257 · Cited by 8
“However, the successful clinical application of these in vivo technologies has primarily been restricted to the liver and current platforms are limited in the amount of genetic information they can deliver to cells , typically limited to a single gene due to packaging limitations 9, 10 .”
Cas9 RNP Physiochemical Analysis for Enhanced CRISPR-AuNP Assembly and FunctionPreprint
Lane, D. D., Gottimukkala, K. S. V., Cunningham, R. A., Jwa, Y., Cassidy, M. E., Castelli, J. M. P., & Adair, J. E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.586657 · Cited by 5
Base Editing Gene Therapy for Heterozygous Familial HypercholesterolemiaPreprint
Wan, P., Tang, S., Lin, D., Lu, Y., Long, M., Xiao, L., Jiang, Y., Liao, J., Ma, X., Liu, Y., et al. (2025) · medRxiv · doi:10.1101/2025.04.17.25325983 · Cited by 6
The RNA delivery dilemma—lipid versus polymer nanoparticle platforms
Martins, C., Mitchell, M. J., Peer, D., Perrie, Y., Siegwart, D. J., Alonso, M. J., & Aparicio-Blanco, J. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02044-6 · Cited by 14
Marques, N. S., Rosa, S. A., Cordeiro, F., Fernandes, R., Ferreira, C., Bento, D., Brito, D. A., Cardim, N. M., Lopes, L. R., & Azevedo, O. M. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.11.009 · Cited by 8
The Potential of RNA Therapeutics in Treating Cardiovascular Disease
Mainkar, G., Ghiringhelli, M., & Zangi, L. (2025) · Drugs · doi:10.1007/s40265-025-02173-1 · Cited by 7
“Systemic administration of NTLA-2001 in a small phase 1 study was associated with significant reduction in serum TTR concentrations, indicating successful gene knockdown (Table 2) [94].”
Hematopoietic stem cell therapy with gene modification to treat sickle cell disease
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf042 · Cited by 8
CRISPR-epigenetic crosstalk: From bidirectional regulation to therapeutic potential
Wei, Y., Sun, J. Y., & Zhu, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.031 · Cited by 7
CRISPR and gene editing technologies for bleeding disorders
VandenDriessche, T., Janssens, M., & Chuah, M. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251387402 · Cited by 4
“123,124 AAV vectors have been used to deliver the F8 or F9 donor transgenes into the hepatocytes since DNA delivery with LNPs is not as efficient as RNA delivery.”
Tan, T., Diao, Y., Yu, X., Chen, L., & Fang, H. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.044 · Cited by 9
CRISPR–Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis
Ishida, S., Sato, Y., Chosa, K., Ezawa, E., Yamauchi, Y., Oyama, M., Kozuka‐Hata, H., Ito, R., Sato, R., Maeki, M., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-025-02949-6 · Cited by 7
Tounekti, O., Shubow, S., Wassmer, S., Tuyl, A. V., Yang, L., Gong, B., Abhari, M. R., Kalina, W. V., Myler, H. A., DelCarpini, J., et al. (2025) · Bioanalysis · doi:10.1080/17576180.2025.2586976 · Cited by 6
Self-citationPorcari, A., Cuddy, S. A. M., Metra, M., Emdin, M., Fontana, M., & Gillmore, J. D. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106773 · Cited by 5
Self-citationAdvances in Engineered Virus-Like Particles for Genome Editing and Therapy
Son, S. H., Woo, S., Choi, A., Ahn, S., & Yoo, H. C. (2026) · BioDrugs · doi:10.1007/s40259-026-00767-z · Cited by 5
“In particular, LNP-mediated delivery has established liver-directed in vivo editing as a clinical reality [18, 19, 90].”
Seelan, A., Shah, L., Shamshad, S., Khanda, M., Vira, D., Singh, H., Chopra, H., & Greig, N. H. (2026) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2026.01.035 · Cited by 5
“In parallel, peptide-assisted and cell-penetrating peptide-based delivery approaches facilitate carrier-free cytosolic entry of Cas12a ribonucleo-proteins, reducing formulation complexity while maintaining activity [69,70].”
Chen, K., Wang, W., Lennon, A. C., McClure, R. A., Vuchkovska, A., Kelley, S. O., & Wang, Z. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx4097 · Cited by 4
Improving the efficiency of high-fidelity Cas9 by enhancing PAM-distal interactions
Zheng, R., Lu, Z., Wei, R., Shin, Y.-C., Du, J., Zhang, Q., Li, J., Wang, X., Wei, Y., Liu, B., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01753-3 · Cited by 5
Cunningham, R. A., Gottimukkala, K. S. V., Lane, D. D., Poljakov, K., Lipson, P., Enstrom, M., Rizzi, A. M., Chapuis, A. G., & Adair, J. E. (2026) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500242 · Cited by 6
Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities
Zheng, Y., Gao, Y., Guo, M., Wang, L., Zheng, X., Liao, Y., Li, Y., Zhu, J.-P., & Wei, J. (2026) · MedComm · doi:10.1002/mco2.70765 · Cited by 9
Efficient prime editing in vivo and in vitro using lipid nanoparticles
Jiang, A. Y., Cristian, A., Brooks, D. L., Feierman, E. R., Chen, P., Whittaker, M. N., Pierce, S. E., Sakai, H. A., Chen, H., Liu, D., et al. (2026) · Nature Nanotechnology · doi:10.1038/s41565-026-02200-6 · Cited by 7
“Lipid nanoparticles (LNPs) are a promising non-viral delivery modality and have already mediated therapeutic in vivo delivery of mRNA encoding Cas9 nucleases 14 and base editors (BE) 15–17 in animals and in human patients.”
Strategies and mechanisms of precision genome engineering: From gene editing to genome writing
Huang, K., Tian, J., Zhao, W., Zhang, S., Xiang, L., Yang, M., Ls, L., Huang, Y., Zhang, N., Sun, L., et al. (2026) · iMetaOmics. · doi:10.1002/imo2.70115 · Cited by 9
Recent advances in CRISPR/Cas9-assisted gene therapy
Srivastava, A., Chauhan, S., & Ahuja, V. (2023) · Karbala International Journal of Modern Science · doi:10.33640/2405-609x.3330 · Cited by 6
“…in a bacterium, the CRISPR acts as a genomic memory from the previous I n - v i v o D o s e - d e p e nd e n t d e c r ea s e i n s e r u m TT R [ 41 ] R e n a l c e ll c a r c i n o m a C D 7 0 E x - v i v o O n go i n g ( N C T 04438083 ) [ 42 ] M u l t i p l e m y e l o m a B C M A E x - v i…”
BackgroundSpecific Therapy in Transthyretin Amyloid Cardiomyopathy
Saro, R., Allegro, V., Merlo, M., Dore, F., Sinagra, G., & Porcari, A. (2024) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.03.005 · Cited by 3
Silencers Versus Stabilizers in Amyloid Cardiomyopathy. Are We Asking the Wrong Questions?
Falk, R. H., Cuddy, S. A. M., & Zadok, O. I. B. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3614 · Cited by 4
Progress in Gene Therapy for Hereditary Tyrosinemia Type 1
Thomas, H., & Carlisle, R. C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030387 · Cited by 6
“…potential therapeutic power of CRISPR-Cas technology is being realised in early-phase clinical trials where it has demonstrated the ability to knockout specific genes within human cells to produce disease-alleviating or curative results from a single IV administration of liver trophic LNPs [33–35].”
Zang, S.-S., Zhang, R., Zhang, J.-R., Zhang, X., & Li, J. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.262 · Cited by 6
“76 It utilized a lipid nanoparticle delivery system with liver tropism, which carried mRNA encoding SpCas9 and an sgRNA targeting TTR.”
Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges
Yang, P., Khoshandam, M., Bhia, I., Raji, S., Soltaninejad, H., Hosseinkhani, S., Sani, M., Hamidieh, A. A., & Sheykhhasan, M. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101068 · Cited by 10
“The study found that NTLA-2001 caused minimal adverse effects and reduced TTR protein serum levels by specifically targeting the knockout of TTR [ 85 ].”
Gertz, M. A., Aras, M. A., Bart, N., Brannagan, T. H., Griffin, J. M., Kontorovich, A., & Rosen, A. M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2536755 · Cited by 5
“Clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) is a gene editing approach, the aim of which is to permanently edit the TTR gene in hepatocytes, leading to a sustained decrease in the production of TTR [183].”
CRISPR-Cas9-Loaded Lipid Nanoparticles: A Promising Strategy for Targeted Gene Editing and Therapy
Ebrahimi-Khezrabad, S., Aghdasia, M., Zare‐Zardini, H., Eslami, H., & Eskandari, F. (2025) · BioNanoScience · doi:10.1007/s12668-025-02094-z · Cited by 6
“Similarly, a single administration in monkeys resulted in approximately 70% gene editing and greater than 95% reduction in total kallikrein protein and its activity [84].”
In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential
Qin, J., Qiu, Z., Fan, Y., Xiong, Q., Lei, Z., Wei, J., van der Harst, P., Minnema, M. C., Sluijter, J. P. G., van Mil, A., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf152 · Cited by 6
“187 Also, studies using mAbs that specifically targeted disease-associated WT and variant ATTR aggregates in normal mice have yielded encouraging results.”
Advancements in Nonviral Gene Editing Strategies for Rare Diseases
Pérez-Maroto, J., Sepp‐Lorenzino, L., Castaño-Esteban, D., Palacios, D., & Sot, B. (2025) · Human Gene Therapy · doi:10.1177/10430342251372056 · Cited by 6
Self-citationRecent advances and clinical prospects of non-viral brain-targeted gene delivery systems
Wang, S., Xu, L.-L., Ma, F., Xu, M., Chen, G., Wang, D., Wu, X., Wang, P., Yu, J., & Shi, L. (2025) · Applied Physics Reviews · doi:10.1063/5.0255745 · Cited by 4
Graves, L. E., Viswanath, L., van Dijk, E. B., Zhu, E., Koyyalamudi, S. R., Wotton, T., Rosser, S. P. A., Srinivasan, S., Ginn, S. L., & Alexander, I. E. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.011 · Cited by 4
Shor, O., Rabinowitz, R., Offen, D., & Benninger, F. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.026 · Cited by 4
“Recently, the field of gene-editing has entered a new era, as the CRISPR-Cas system was introduced into patients cells, ex vivo [6– 9] and in viv o [10], and reportedly contributing positive results in clinical outcomes.”
BackgroundSuccinct Amyloid and Nonamyloid Patterns in Hexapeptides
Keresztes, L., Szögi, E., Varga, B., Farkas, V., Perczel, A., & Grolmusz, V. I. (2022) · ACS Omega · doi:10.1021/acsomega.2c02513 · Cited by 4
König, S., Fliegauf, M., Rhiel, M., Grimbacher, B., Cornu, T. I., Cathomen, T., & Mussolino, C. (2022) · Genes · doi:10.3390/genes13101912 · Cited by 4
“The introduction of indel mutations into the coding regions of genes has been explored in the last decade to develop therapies for a variety of human disorders, with the first clinical results recently published [17,18].”
BackgroundYamada, N., & Aruga, A. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00481-2 · Cited by 6
“ChIP-Seq [50], GUIDE-Seq [51], and HTHTS[52] were developed as cell-based methods during this period, and GUIDE-Seq was used in preclinical studies of EDIT101, NTLA-2001, and GPH101.”
BackgroundMethodResultInfluentialNo crops without seeds: the risks in declining support for fundamental research
Hogan, B. M., Kahn, M. L., & Harvey, N. L. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00225-x · Cited by 4
Qureshi, A., & Connolly, J. B. (2023) · Malaria Journal · doi:10.1186/s12936-023-04665-5 · Cited by 5
“[97] reported delivery of intravenous injections of mRNA encoding Cas9 and a gRNA targeting the transthyretin gene encapsulated in lipid nanoparticles in six patients with life-threatening transthyretin amyloidosis.”
BackgroundMonitoring cardiac amyloidosis with multimodality imaging
Starr, N., Ioannou, A., & Martinez–Naharro, A. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.06.014 · Cited by 11
Ameratunga, R., Leung, E. Y., Woon, S., Lea, E., Allan, C. L. M., Chan, L., Longhurst, H. J., Steele, R., Snell, R. G., & Lehnert, K. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109854 · Cited by 8
Caobelli, F. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266676 · Cited by 4
Delivery of Rna Drugs: Beyond the Liver, More than Vaccine
Elnaggar, M. G., He, Y., & Yeo, Y. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114203 · Cited by 5
Delrue, C., Dendooven, A., Vandendriessche, A., Speeckaert, R., Bruyne, S. D., & Speeckaert, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115875 · Cited by 4
“New therapies like clustered regularly interspaced short palindromic repeats ( CRISPR ) gene editing have demonstrated potential in lowering serum TTR levels, thereby providing a long-term remedy for ATTRv management [85,86].”
BackgroundPharmacological management of transthyretin amyloid cardiomyopathy: a scoping review
Rehman, S., Masthan, S. S., Ibrahim, R., Pham, H. N., Hassan, D., Ahmad, F., Asif, M. S., Safdar, A., Anwar, Z. U. A., Raza, S., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae044 · Cited by 7
Engineering CRISPR for emerging therapeutic applications
Sun, X., & Liu, Z. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100035 · Cited by 4
Sekar, P. K. C., & Veerabathiran, R. (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000136 · Cited by 6
Togashi, T., Baatartsogt, N., Nagao, Y., Kashiwakura, Y., Hayakawa, M., Kamoshita, N., Hiramoto, T., Fujiwara, T., Morishita, E., Nureki, O., et al. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319460 · Cited by 4
“52 In the future, simultaneously administering lipid nanoparticle for transient Cas9 expression with an AAV vector as a donor sequence for gene insertion in the liver in vivo would be a better strategy.”
Laptseva, N., Benz, D. C., Schwotzer, R., et al. (2024) · Swiss Medical Weekly · doi:10.57187/s.4186 · Cited by 4
Phospholipase C epsilon 1 as a therapeutic target in cardiovascular diseases
Wang, J., Gao, T., Zhang, D., Tang, Y., & Gu, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.01.032 · Cited by 6
“Additionally, the occurrence of adverse events was mild [171].”
Yu, M., Ai, L., Wang, B., Lian, S., Ip, L., Liu, J., Li, L. X., Tsai, S. Q., Kleinstiver, B. P., & Zheng, Z. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01464-y · Cited by 6
“However, GUIDE-seq has been one of the main methods for assessing CRISPR off-target effects in both research and therapeutic settings 48,49 .”
The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives
Rapezzi, C., Vergaro, G., Emdin, M., Fabbri, G., Cantone, A. F., Sanguettoli, F., & Aimo, A. (2022) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.21.05926-3 · Cited by 5
Homology directed correction, a new pathway model for point mutation repair catalyzed by CRISPR-Cas
Sansbury, B. M., Hewes, A. M., Tharp, O. M., Masciarelli, S. B., Kaouser, S., & Kmiec, E. B. (2022) · Scientific Reports · doi:10.1038/s41598-022-11808-2 · Cited by 5
CRISPR comes a-knock-in to reprogram antibodies in vivo
Hartweger, H., & Nussenzweig, M. C. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01299-x · Cited by 4
Therapeutic applications of gene editing in chronic liver diseases: an update
Shin, J. H., Lee, J., Jung, Y. K., Kim, K. S., Jeong, J., & Choi, D. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.6.033 · Cited by 5
“A recent study reported that a single administration of NLTA-2001, an in vivo gene-editing therapeutic agent, decreases the level of serum transthyretin (TTR) in patients, indicating potent therapeutic efficacy (61).”
BackgroundThe CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective
Lattanzi, A., & Maddalo, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0002 · Cited by 4
“56,57 58–60 These studies have triggered the development of a wide range of novel LNP formulations targeting specific tissues such as bone marrow, endothelial cells, kidney, brain, and lung.”
Jiang, M., Wang, M., Tao, Z., et al. (2022) · Amyloid · doi:10.1080/13506129.2022.2142109 · Cited by 4
“It also calls for the need to develop new therapeutic strategies to generally treat TTR amyloidosis without discriminating by mutant types, such as siRNA silencing and CRISPR-Cas9-mediated gene editing [30].”
BackgroundNatural history and survival rate of familial amyloidosis with polyneuropathy: A nationwide databank
Tseng, W., Huang, H., Li, C., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51765 · Cited by 4
Zou, H., & Zhou, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814146 · Cited by 6
“Gene editing therapy [23] is a clustered, regularly spaced, short palindromic repeat-sequence-based Cas9 nucleic acid endonuclease (CRISPR-Cas9) therapy, represented by NTLA-2001 [24], which is currently in the early stages of clinical research.”
BackgroundDevelopment and assessment of cutting-edge biotechnologies
Hu, X., Xu, B., Chen, M., Li, K., Xiao, Y., Liang, S., Zhang, C., Ma, H., & Song, H. (2024) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2024.03.001 · Cited by 6
Major advances in neuromuscular disorders in the past two decades
Wadman, R. I., van Rheenen, W., van der Pol, W. L., & van den Berg, L. H. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00190-9 · Cited by 4
Sckaff, M., Gill, K., Sachdev, A., Birk, A. M., Arogundade, O. A., Watry, H., Keough, K. C., Tsai, Y.-C., Ziegle, J. S., Conklin, B. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.21.492887 · Cited by 5
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B. P., & Lee, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.28.538700 · Cited by 4
Nuclear βII-Tubulin and its Possible Utility in Cancer Diagnosis, Prognosis and Treatment
Ludueña, R. F., Walss‐Bass, C., Portyanko, A., Guo, J., & Yeh, I. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.870088 · Cited by 3
“For any agent involving CRISPR-Cas9, there would be three questions that need to be answered: First, how could a βII-CRISPR-Cas9 complex enter the target cell? If there is a receptor on the tumor cell membrane then it may be possible to add to the complex a factor that would bind to the receptor, for example, a lipid…”
BackgroundA qPCR Method to Assay Endonuclease Activity of Cas9-sgRNA Ribonucleoprotein Complexes
Nguyen, M. T., Kim, S.-A., Cheng, Y., Hong, S. H., Jin, Y., & Han, N. S. (2023) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2305.05010 · Cited by 3
“Clustered regularly interspaced short palindromic repeats (CRISPR) and their associated proteins (Cas) are adaptive immune systems of prokaryotes against foreign DNA, including phages, viruses, and plasmids [1, 2].”
BackgroundHemodynamics in Left-Sided Cardiomyopathies
Monaco, G. D., Amata, F., Battaglia, V., Panico, C., Condorelli, G., & Pinto, G. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2512455 · Cited by 4
High‐Risk HPV Oncoproteins and PD‐1/PD‐L1 Interplay
Zhen, S. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70415 · Cited by 4
“The impact of the PD ‐ 1/PD ‐ L1 axis in chronic virus infections is well described whereas its role during the acute phase of viral infections is less clear [64 – 66].”
Alfarano, M., Ciccarelli, F., Marchionni, G., Ballatore, F., Costantino, J., Lattanzio, A., Pecci, G., Stavagna, S., Iannelli, L., Galardo, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124228 · Cited by 5
Development of aerosolizable mRNA incorporated chitosan nanoparticles for efficient lung delivery
Kota, S. S. N., Moore, E., Tolman, J. A., & Dash, A. K. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126104 · Cited by 4
Transthyretin Amyloid Cardiomyopathy Treatment: An Updated Review
Wanniarachchige, D., Khan, S. P., & Pan, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176089 · Cited by 3
“The goal of this therapy is to introduce frameshift mutations in the TTR gene, thereby preventing the production of both wildtype and mutant TTR, which are responsible for amyloid deposition [Figure 2] [23].”
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



